This issue takes a deep dive into one of the most dynamic areas of precision oncology. MabDesign’s Scientific and Business Intelligence Department kicks off the edition with an in-depth analysis of the market landscape, development pipeline, and industrial challenges shaping this consolidating sector.
Leading experts then address critical topics: from bioconjugation strategies for radioimmunoconjugates to targeted alpha immunotherapy for bladder cancer, as well as the collaborative ecosystem supported by the PROMETHE association and the role of artificial intelligence in discovering novel radiotheranostic targets.
Link to the original article: 2026-IW-Radiopharmaceuticals-5.pdf